Amgen Inc. Effective Income Tax Rate Reconciliation Fdii Percent
Amgen Inc. (AMGN) reported Effective Income Tax Rate Reconciliation Fdii Percent of 2.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent · last filed 2026-02-13
- Amgen Inc. effective income tax rate reconciliation fdii percent for fiscal 2025 was 2.50%, a 16.67% decline from fiscal 2024.
- Amgen Inc. effective income tax rate reconciliation fdii percent for fiscal 2024 was 3.00%, a 130.77% increase from fiscal 2023.
- Amgen Inc. effective income tax rate reconciliation fdii percent for fiscal 2023 was 1.30%, a 0.00% change from fiscal 2022.
- Amgen Inc. effective income tax rate reconciliation fdii percent for fiscal 2022 was 1.30%, a 30.00% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation Fdii Percent 12 month |
|---|---|
| 2025-12-31 | 2.50% 10-K · filed 2026-02-13 |
| 2024-12-31 | 3.00% 10-K · filed 2026-02-13 |
| 2023-12-31 | 1.30% 10-K · filed 2026-02-13 |
| 2022-12-31 | 1.30% 10-K · filed 2025-02-14 |
| 2021-12-31 | 1.00% 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |